Monoclonal Antibody News and Research

RSS

Monoclonal antibodies (MAbs) are produced from a single B cell clone and can bind to a single type of antigen binding site. MAbs are homogenous antibodies that cannot form lattices with monomeric proteins as they can bind to only a single epitope on the antigen. Developed in the 1970s, MAbs can be produced against any given substance. Thus they can be used to detect and purify any substance of interest. This has made MAbs a powerful tool of molecular biology, biochemistry, and medicine.

The duration of the infectious stage of individuals infected with the SARS-CoV-2 Omicron variant

Researchers demonstrated clinical features and infectivity of the currently dominant SARS-CoV-2 variant of concern Omicron, compared to Delta, the previously dominant VOC.

3 Oct 2022

Universal vaccine advancement through AI and recombinant technology

In this interview, News-Medical talks to Dr. Amy Sheng and Dr. Lurong Pan about how AI computing can be used in combination with high throughput production and screening to enhance the development process for potential universal vaccines.

From Sino Biological Inc. 3 Oct 2022

Houston Methodist researchers receive CPRIT funding to research two of the most lethal cancers

Two Houston Methodist cancer researchers have been awarded a half million dollars in funding from the Cancer Prevention and Research Institute of Texas to further research two of the most lethal, difficult-to-treat cancers that all-too-often have poor prognoses.

28 Sep 2022

Food, vaccines, bacteria, and viruses may all prime our immune system to attack SARS-CoV-2

Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), the causal agent of the ongoing coronavirus disease 2019 (COVID-19) pandemic, primarily causes mild to moderate upper-respiratory tract illness. However, some individuals with COVID-19 develop severe infections and require hospital admission.

27 Sep 2022

Study finds remdesivir-resistant version of COVID-19 in renal transplant recipients

Recent studies have shown that patients with weakened immune systems—which enables the virus that causes COVID-19 to remain longer in the body, copy itself, and continually change—may enable the development of new, slightly different versions of the virus (variants).

26 Sep 2022

Study demonstrates how pan-sarbecovirus ORF7a protein plays a role in evading host immunity

In a new study, researchers demonstrated how sarbecovirus family down-regulates major histocompatibility complex-I (MHC-I) surface expression to evade cellular immunity.

26 Sep 2022

Common germline variants of APOE contribute to differential COVID-19 outcomes

Researchers investigated the relationship between APOE4 genotype and COVID-19 outcomes using genetic models of mice.

26 Sep 2022

Stanford Medicine study shows SARS-CoV-2 can infect human fat tissue

Is SARS-CoV-2 hiding in your fat cells? A study by Stanford Medicine investigators shows that SARS-CoV-2 can infect human fat tissue.

22 Sep 2022

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

In a recent study published in the journal PNAS, researchers from Finland and the United States reported a novel heptad repeat 2 (HR2) peptide that inhibited severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) without any chemical modifications.

21 Sep 2022

Study reveals increased immunity evasion by Omicron BA.2.75.2

In a recent study posted to the bioRxiv* preprint server, researchers from ETH Zurich, Imperial College London, and Karolinska Institutet identified increased resistance to antibody-mediated neutralization by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sublineage BA.2.75.2.

21 Sep 2022

Itchy eczema in children finally gets relief

This is the first large-scale, randomized, placebo-controlled trial of a monoclonal antibody in any skin disease, including eczema, in children as young as six months. The study, which included 31 sites in Europe and North America, was published in The Lancet.

16 Sep 2022

BU researcher awarded $7.2 million grant to develop mAb-based contraceptive products

Deborah Jean Anderson, PhD, professor of medicine at Boston University School of Medicine, has received a four-year, $7.2 million grant from the NIH's National Institute of Child Health and Human Development renewing support for a Contraceptive Research Center at BUSM to further her research to develop innovative monoclonal antibody (mAb)-based contraceptive and multipurpose prevention technology (MPT) products.

15 Sep 2022

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

In an article published in the journal Expert Opinion on Drug Safety, scientists have described the safety and efficacy profiles of anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) monoclonal antibodies in pregnant women with coronavirus disease 2019 (COVID-19).

13 Sep 2022

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

In a recent study posted to the bioRxiv* preprint server, researchers in Taiwan and the United States explore the resistance of a newly emergent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron sub-variant BA.4.6 to the therapeutic monoclonal antibodies currently being used to treat coronavirus disease 2019 (COVID-19).

12 Sep 2022

All SARS-CoV-2 variants neutralized by a potent new antibody

Researchers describe a mouse model used to generate a VH1-2 heavy chain (HC)- and Vκ1-33 light chain (LC)-based recombinant antibody that broadly neutralized all severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variants, including the newly emergent Omicron sub-variant BA.5.

9 Sep 2022

AbbVie to present data from its robust migraine portfolio at the Migraine Trust International Symposium 2022

AbbVie today announced that new data from its migraine portfolio will be presented at the Migraine Trust International Symposium (MTIS) 2022, taking place in London from September 8-11.

From AbbVie 8 Sep 2022

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

In a recent study posted to the bioRxiv* preprint server, researchers at the U.S National Institutes of Health demonstrated the efficacy of molnupiravir and nirmatrelvir, two oral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antivirals in the rhesus macaque model, the closest proxy to humans.

7 Sep 2022

Novel P22-mAb based bELISA assay can help detect antibodies against African swine fever virus

African swine fever (ASF) is a highly infectious and fatal disease of pigs. Due to the complexity of the ASF virus (ASFV) and various clinical forms of the disease, a wide range of highly effective and robust sero-diagnostic assays are required.

2 Sep 2022

Research reveals administration of ineffective COVID-19 treatments after FDA deauthorization

Monoclonal antibodies are laboratory-designed treatments tailor-made to fight specific infections. In early 2021, the U.S. Food & Drug Administration issued emergency use authorization for two monoclonal antibodies (bamlanivimab/etesevimab and casirivimab/imdevimab) for the treatment of mild to moderate COVID-19 in high-risk, non-hospitalized patients.

30 Aug 2022

Survey reveals clear differences among the NYC boroughs in COVID behaviors and attitudes

As the nation follows new CDC recommendations to relax COVID-19 restrictions, a new survey of 2,500 New Yorkers conducted by the CUNY Graduate School of Public Health and Health Policy (CUNY SPH) revealed clear differences among the boroughs in vaccine and booster uptake, childhood vaccination, treatment when sick and general trust in the safety and effectiveness of the vaccine.

24 Aug 2022

Monoclonal Antibody News and Research

Further Reading

The duration of the infectious stage of individuals infected with the SARS-CoV-2 Omicron variant

Universal vaccine advancement through AI and recombinant technology

Houston Methodist researchers receive CPRIT funding to research two of the most lethal cancers

Food, vaccines, bacteria, and viruses may all prime our immune system to attack SARS-CoV-2

Study finds remdesivir-resistant version of COVID-19 in renal transplant recipients

Study demonstrates how pan-sarbecovirus ORF7a protein plays a role in evading host immunity

Common germline variants of APOE contribute to differential COVID-19 outcomes

Stanford Medicine study shows SARS-CoV-2 can infect human fat tissue

All SARS-CoV-2 variants blocked by a simple peptide with nanomolar neutralizing efficacy

Study reveals increased immunity evasion by Omicron BA.2.75.2

Itchy eczema in children finally gets relief

BU researcher awarded $7.2 million grant to develop mAb-based contraceptive products

Efficacy and safety of monoclonal antibodies against SARS-CoV-2 during pregnancy

SARS-CoV-2 Omicron BA.4.6 resistant to many therapeutic monoclonal antibodies in clinical use

All SARS-CoV-2 variants neutralized by a potent new antibody

AbbVie to present data from its robust migraine portfolio at the Migraine Trust International Symposium 2022

NIH animal study combines Paxlovid with Lagevrio against SARS-CoV-2 Delta

Novel P22-mAb based bELISA assay can help detect antibodies against African swine fever virus

Research reveals administration of ineffective COVID-19 treatments after FDA deauthorization

Survey reveals clear differences among the NYC boroughs in COVID behaviors and attitudes

Antibodies eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News